Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Developments in Big, Open Access Data for Dementia

Published: Thursday, June 19, 2014
Last Updated: Monday, June 23, 2014
Bookmark and Share
Prime Minister, David Cameron, pledged a UK commitment to discover new drugs and treatment that could slow down the on-set of dementia or even deliver a cure by 2025.

This was aligned with the official launch of the MRC’s UK Dementias Research Platform (UKDP)announced by Secretary of State for Health, Jeremy Hunt, at the first Global Dementia Legacy Event held in London.

Imperial College London researchers are heavily involved in the UKDP big data initiative, which joins together ongoing studies across the UK to provide a research population approaching nearly 2 million people. They are also playing an important role in the largest of the contributing studies – the UK Biobank - which has recently started collecting imaging data on 100,000 participants, including scans of brains, hearts, bones and blood vessels.

Data from UK Biobank will be open access, allowing researchers from anywhere within the UK to tap into this vast resource. When possible, data from other studies in the UKDP will also will be made open access, promising a uniquely powerful way of enabling new discovery.  

Dr Craig Ritchie from theDepartment of Medicine, Imperial College London who is on the UKDP steering committee said: “This really is a game changer in dementia research and will be a phenomenal resource to answer the big questions. It will enable the research community to move seamlessly between different levels of data, which simply could not happen if we worked in our own separate research groups and areas. By involving major players in the pharmaceutical and biotechnology industries, the platform will accelerate discovery of new treatments and interventions and allow the UK to take a leading role in the design and delivery of programmes to stop the progression of dementia.”

The UKDP is a public-private partnership that brings together top academic knowledge and cutting-edge technologies. The 22 studies that fall under its information umbrella will provide a research population approaching nearly 2 million people to evaluate dementia risk.  Bringing this data together will allow researchers to scale up individual studies to explore their significance in larger populations, and also to drill down into more specific data that is only available in smaller samples. For example, if researchers want to investigate dietary links to dementia at a population level they can investigate the biologically possibility of this in a smaller study with specific genetic data.

Amongst the 22 studies are the Imperial College London CHARIOT project (Cognitive Health in Ageing Register: Investigational, Observational and Trial studies in dementia research) which is a register of over 20,000 elderly people and  PREVENT  which is an ambitious pilot project into mid-life to try to identify biological markers of the disease.

The UK Biobank will be the largest project under the new UKDP data umbrella. This was launched to collect a range of health data on 500,000 people. One of its several goals is to understand the course of Alzheimer’s over time. In May, the UK Biobank launched the world’s most ambitious research imaging programme that will collect brain, heart, blood vessel and bone scans from 100,000 participants.  Scanning has begun in a single centre that is rapidly increasing its numbers, setting the ambitious goal of performing 18 full sets of scans and associated clinical examinations per day by September.

From the beginning of this ambitious project, researchers from Imperial College London have been involved in planning and translating the UK Biobank and its Imaging Enhancement from initial concept to current reality. Professor Paul Matthews Head of the Division of Brain Sciences in Department of Medicine at Imperial College London chairs the Imaging Working Group of the UK Biobank that initiated this recent addition to the observational studies. Several additional investigators from Imperial and other universities have developed the protocols for the different types of scan to ensure the data is correctly collected, stored and able to be shared.

“The Biobank promises to bring a new level of understanding to the risk of later life disease such as dementia,” says Professor Matthews. “It also shows the scientific community working together to address big challenges to answer important questions. No one will have special access to this rich dataset, although the many scientists volunteering their time to support the project are ensuring that it is truly ‘state of the art’. From the start, Imperial researchers have driven its development, moving it from a simple concept to the huge resource it will become in the near future. We are committed to this new scientific environment where open data creates a space for greater innovation and faster translation into treatment.”

Collaboration and knowledge-sharing is at the heart of these initiatives. Imperial College London is keen to open its doors further to this exciting new development in dementia research. It hosts the national Parkinson’s Disease Society brain bank and the MRC-NIHR National Phenome Centre, which helps provide a basis for evaluating the phenomes (combination of physical and personal traits) that are important in dementia. The recently launched Imperial Data Science Institute is also committed to exploring important questions around healthcare strategy and particularly dementia.

Consultant psychiatrist and Co-Director of the Neuroepidemiology and Ageing Research Department at Imperial College London, Dr Robert Perneczky said: “The UKDP and the UK Biobank will contribute significantly to developing treatments and interventions for dementia. We still don’t really understand the disease and this is why there are currently no viable treatments. By collecting and amassing data at a population level we can bridge this knowledge gap by tracing progression of the disease, identifying markers that can indicate onset, and discovering new treatments and interventions that can be applied as early as possible. By using big data and opening it up to innovation we can now start to take big steps towards preventing and halting dementia.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Discovery of Trigger for Bugs’ Defences Could Lead to New Antibiotics
New research shows that sigma54 holds a bacterium’s defences back until it encounters stress.
Friday, August 21, 2015
Breakthrough Could Lead to New Antibiotics
Scientists have exposed a chink in the armour of disease-causing bugs, with a new discovery about a protein that controls bacterial defences.
Friday, August 21, 2015
New Drug Target Identified for Serious Heart and Lung Condition
A gene has been identified that sheds new light on a potentially fatal heart and lung condition and could lead to a new treatment.
Friday, August 14, 2015
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Saturday, August 01, 2015
Fossil Fuel Emissions will Complicate Radiocarbon Dating, Warns Scientist
The paper is published in the journal PNAS.
Tuesday, July 21, 2015
Scientists Find New Variant of Streptococcal Bacteria Causing Severe Infections
Researchers noticed a sharp rise in infections caused by emm89.
Wednesday, July 15, 2015
Gene Therapy for Cystic Fibrosis Shows Encouraging Trial Results
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial.
Friday, July 03, 2015
New Genetic Form of Obesity and Diabetes Discovered
Scientists have discovered a new inherited form of obesity and type 2 diabetes in humans.
Tuesday, June 30, 2015
New Genetic Form of Obesity and Diabetes Discovered
Scientists have discovered a new inherited form of obesity and type 2 diabetes in humans.
Tuesday, June 30, 2015
Researchers Develop New Breath Test to Diagnose Oesophageal and Gastric Cancer
Test will now be tested in a larger trial involving three hospitals in London.
Tuesday, June 23, 2015
'Crumpled' Filter to Slash Energy Consumption
Scientists have developed an ultra-thin, super-strong membrane to filter liquids and gases, with the potential to cut energy consumption in industry.
Friday, June 19, 2015
Imperial Researchers Win Health Foundation Grant for Cancer Innovation Study
Each project will receive over £450,000 of funding to support the research.
Tuesday, May 26, 2015
Engineering Bacteria for Vaccine Delivery
An eight million Euro project has been launched with the aim of engineering bacteria to deliver vaccines against antibiotic-resistant infections.
Monday, May 18, 2015
Diet Swap has Dramatic Effects on Colon Cancer Risk for Americans and Africans
New study confirms that a high fibre diet can substantially reduce risk.
Saturday, May 02, 2015
Alcoholic Hepatitis Treatments Fail to Keep Patients Alive
The study is published in the New England Journal of Medicine.
Friday, May 01, 2015
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!